Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case - A modern Pandora's box

Biomedicine and Pharmacotherapy

Volumn 56, Issue 1, 2002, Pages 56-59

  Bliznakov, E G ^a  

^a Biomedical Research Consultants   (United States)

Author keywords

Cardiovascular diseases; Cholesterol; Coenzyme Q10; HMG CoA reductase inhibitors; Oxidative stress; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; GEMFIBROZIL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN; TRIACYLGLYCEROL; UBIDECARENONE;

ANGIOGENESIS; ANTICOAGULATION; CARDIOVASCULAR DISEASE; CATARACT; DRUG EFFICACY; DRUG POTENCY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MENTAL DISEASE; MYOPATHY; NEOPLASM; OSSIFICATION; PATHOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

EID: 0036177616     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(01)00150-0     Document Type: Note

References (24)

1. Effects of inhibitors of hydroxymethylglutaryl coenzyme A reductase on coenzyme Q and dolichol biosynthesis
2. Medical ethics
3. Biochemical and clinical consequences of inhibiting coenzyme Q biosynthesis by lipid-lowering HMG-Co A reductase inhibitors (statins): A critical overview
4. Effect of simvastatin therapy on blood and tissue ATP levels and erythrocyte membrane lipid composition
5. Executive summary of the Third Report of the National Cholesterol Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
6. Low-density lipoprotein-independent effects of statins
7. Statins and cancer: A case of meta-uncertainty
8. Lotronex and the FDA: A fatal erosion of integrity - Commentary
9. Pleiotropic effects of statins and their clinical significance
10. Physicians and the pharmaceutical industry: Is a gift ever a gift?